Shanghai Fosun Pharma's subsidiary to buy GlaxoSmithKline plant

2019-07-09 18:56

Already collect

HANGZHOU, July 9 (Xinhua) -- Shanghai Fosun Pharmaceutical (Group) Co. Ltd. will spend up to 250 million yuan (36 million U.S. dollars) to buy GlaxoSmithKline's Suzhou pharmaceutical factory in east China, according to a Fosun statement released Tuesday.

The deal will allow YaoPharma Co., Ltd., Fosun's Chongqing unit, to acquire all production facilities and authorizations for the GSK plant's chronic hepatitis B drug lamivudine.

The factory achieved a revenue of 656.1 million yuan, with a net profit of 73.98 million yuan in 2018, according to the statement.

Fosun Pharmaceutical's shares closed 0.58 percent higher at 26.24 yuan on Tuesday.

Related News
Add comments

Latest comments

Latest News
News Most Viewed